MELBOURNE, AUSTRALIA / ACCESSWIRE / October 26, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced the Company was recently selected by the OTC Markets Group to join the OTCQB Venture Index.

The OTCQB Index is designed as a benchmark for tracking the overall performance of the OTCQB marketplace and serves primarily as a performance benchmark for investors in OTCQB securities. The index highlights entrepreneurial and development stage U.S. and international companies that have been verified to trade on OTCQB.

Further, the OTCQB Index enhances Propanc's visibility in the US Marketplace, providing a fully transparent, highly visible marketplace for the Company's shares.

Interestingly, in the last quarter, one hundred twenty-four were added to the Index as more companies were approved to trade on OTCQB under the stricter market standards and eligibility requirements. One hundred fifty-five companies were removed during the quarter, including 10 companies that graduated to an exchange.

"We are very pleased to have been selected for the OTCQB Index," said James Nathanielsz, Propanc's Chief Executive Officer, "We are also excited to observe that out of the ten companies which graduated to an exchange from the OTCQB in the last quarter, at least several appear to be from the biotech sector."

Propanc aims to fast track the development of proenzyme related oncology products into clinical trials for colorectal and pancreatic tumors, initially. According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through our OTC Link(R) ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into markets to inform investors of opportunities and risks: the OTCQX(R) Best Market; the OTCQB(R) Venture Market; and the OTC Pink(R) Open Market. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial markets, visit www.otcmarkets.com.

About Propanc:

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.

Forward-looking Statements:

Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.

SOURCE:Propanc Health Group Corporation

Grafico Azioni Propanc Biopharma (PK) (USOTC:PPCB)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Propanc Biopharma (PK)
Grafico Azioni Propanc Biopharma (PK) (USOTC:PPCB)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Propanc Biopharma (PK)